DE69708307T2 - 5-alpha REDUCTASE INHIBIERENDE ZUSAMMENSTELLUNG ZUR ORALEN VERABREICHUNG, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG - Google Patents

5-alpha REDUCTASE INHIBIERENDE ZUSAMMENSTELLUNG ZUR ORALEN VERABREICHUNG, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG

Info

Publication number
DE69708307T2
DE69708307T2 DE69708307T DE69708307T DE69708307T2 DE 69708307 T2 DE69708307 T2 DE 69708307T2 DE 69708307 T DE69708307 T DE 69708307T DE 69708307 T DE69708307 T DE 69708307T DE 69708307 T2 DE69708307 T2 DE 69708307T2
Authority
DE
Germany
Prior art keywords
oral administration
production
inhibiting composition
alpha reductase
reductase inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69708307T
Other languages
English (en)
Other versions
DE69708307D1 (de
Inventor
Fusao Usui
Yuko Ohuchi
Akira Kusai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of DE69708307D1 publication Critical patent/DE69708307D1/de
Application granted granted Critical
Publication of DE69708307T2 publication Critical patent/DE69708307T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69708307T 1996-02-05 1997-02-04 5-alpha REDUCTASE INHIBIERENDE ZUSAMMENSTELLUNG ZUR ORALEN VERABREICHUNG, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG Expired - Fee Related DE69708307T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1871896 1996-02-05
PCT/JP1997/000273 WO1997027875A1 (fr) 1996-02-05 1997-02-04 PREPARATION INHIBITRICE DE LA 5α-REDUCTASE ADMINISTRABLE PAR VOIE ORALE, PROCEDE DE PRODUCTION ET UTILISATION

Publications (2)

Publication Number Publication Date
DE69708307D1 DE69708307D1 (de) 2001-12-20
DE69708307T2 true DE69708307T2 (de) 2002-08-14

Family

ID=11979447

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69708307T Expired - Fee Related DE69708307T2 (de) 1996-02-05 1997-02-04 5-alpha REDUCTASE INHIBIERENDE ZUSAMMENSTELLUNG ZUR ORALEN VERABREICHUNG, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG

Country Status (18)

Country Link
US (1) US20020015732A1 (de)
EP (1) EP0923942B1 (de)
KR (1) KR19990082277A (de)
CN (1) CN1215339A (de)
AT (1) ATE208631T1 (de)
AU (1) AU709146B2 (de)
CZ (1) CZ289856B6 (de)
DE (1) DE69708307T2 (de)
DK (1) DK0923942T3 (de)
ES (1) ES2165017T3 (de)
HK (1) HK1020258A1 (de)
HU (1) HUP9901870A3 (de)
MX (1) MX9806292A (de)
NO (1) NO983580L (de)
NZ (1) NZ326897A (de)
PT (1) PT923942E (de)
RU (1) RU2154467C2 (de)
WO (1) WO1997027875A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265854T1 (de) * 1997-02-26 2004-05-15 Sankyo Co Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
ES2218840T3 (es) * 1997-07-29 2004-11-16 Sankyo Company Limited Composicion azasteroide para ael tratamiento de la alopecia, el hirsutismo femenino y la seborrea.
CN110628735B (zh) * 2019-04-23 2022-04-08 天津科技大学 一种5α-还原酶突变体,基因工程菌及其在高效催化5α-AD生产中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
ZA851426B (en) * 1984-02-27 1986-10-29 Merck & Co Inc 17 beta-n-monosubstituted carbamoyl-4-aza-5 alpha-androst-1-en-3-ones as 5 alpha reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
JPH06293793A (ja) * 1993-02-10 1994-10-21 Sankyo Co Ltd ステロイド−17−アミド類の製造法

Also Published As

Publication number Publication date
ES2165017T3 (es) 2002-03-01
CZ234298A3 (cs) 1998-11-11
EP0923942B1 (de) 2001-11-14
HUP9901870A3 (en) 1999-11-29
EP0923942A1 (de) 1999-06-23
PT923942E (pt) 2002-03-28
AU1558997A (en) 1997-08-22
NZ326897A (en) 1999-08-30
CN1215339A (zh) 1999-04-28
ATE208631T1 (de) 2001-11-15
AU709146B2 (en) 1999-08-19
KR19990082277A (ko) 1999-11-25
EP0923942A4 (de) 1999-06-23
DE69708307D1 (de) 2001-12-20
HUP9901870A2 (hu) 1999-09-28
CZ289856B6 (cs) 2002-04-17
MX9806292A (es) 1998-11-30
RU2154467C2 (ru) 2000-08-20
HK1020258A1 (en) 2000-04-07
WO1997027875A1 (fr) 1997-08-07
DK0923942T3 (da) 2001-12-17
US20020015732A1 (en) 2002-02-07
NO983580L (no) 1998-10-02
NO983580D0 (no) 1998-08-04

Similar Documents

Publication Publication Date Title
ATE128143T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung.
DE60126099D1 (de) Kristallines und reines modafinil und verfahren zu seiner herstellung
DE60330703D1 (de) Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
ATE346610T1 (de) Zusammensetzung enthaltend, ein antigen, ein th-1 induzierendes adjuvans und eine im wasser schwer lösliche aminosäure, zur verwendung in der immunisierung
ATE250077T1 (de) Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung
ATA182898A (de) Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
AU3049795A (en) Serotonergic tetrahydropyridoindoles
DE69924846D1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
DE69838146D1 (de) Androgene steroidderivate und ein verfahren zur herstellung und verwendung derselben
DE69708307D1 (de) 5-alpha REDUCTASE INHIBIERENDE ZUSAMMENSTELLUNG ZUR ORALEN VERABREICHUNG, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG
ATE160338T1 (de) Alpha aminosäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE194602T1 (de) Verfahren zur herstellung von 1,4,7,10- tetraazacyclododecan und dessen derivaten
ZA921341B (en) 4-((2-benzothiazolyl)methylamino)-a-(3,4-difluorophenoxy) methyl)-1-piperidineethanol.
DE69705967T2 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
ATE152709T1 (de) Tetrahydrocyclopent(b>indole-methanamine und verwandte verbindungen, und verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE292962T1 (de) Verwendung einer zusammensetzung zur herstellung eines arzneimittels zur vorbeugung und behandlung von parodontitis
ATE401303T1 (de) Verfahren zur herstellung von ed-71
DE59709792D1 (de) Ringannelierte dihydropyrane, verfahren zur herstellung sowie deren verwendung
BR9707004A (pt) Composto processo para preparar o mesmo composição farmacêutica utilização do composto e processos para tratamento de doenças do sistema endocinológico e para a manufatura de um medicamento
ATE251132T1 (de) Verfahren zur herstellung von s-aryl-l-cystein und derivate
ATE360027T1 (de) 11beta-langkettig-substituierte estratriene, verfahren zur herstellung, pharmazeutische präparate, die diese 11beta-langkettig- substituierten estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
ATE154346T1 (de) N-5-geschützte 2,5-diamino-4,6-dichlorpyrimidine und verfahren zu deren herstellung
ATE324798T1 (de) Sirup-enthaltende zusammensetzungen und verfahren zu deren herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee